Library › Cytology laboratory regulations, quality assurance and management
Cytology laboratory regulations, quality assurance and management
Last reviewed 2026-11-10 by a board-certified pathologist. 51 references.
CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation
Definition. The Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) set the federal conditions that every laboratory testing human specimens must meet. The implementing regulations are codified in 42 CFR Part 493, which implements section 353 of the Public Health Service Act and applies to all laboratories, including those seeking Medicare and Medicaid payment (42 CFR 493.1). Cytology is a subspecialty of the specialty of pathology, together with histopathology and oral pathology (42 CFR 493.638(c)(2)(vi)). The cytology standard is 42 CFR 493.1274 in subpart K, the quality system for nonwaived testing. The personnel rules for cytology are in subpart M: the technical supervisor (§493.1449 and §493.1451), the cytology general supervisor (§493.1467 to §493.1471) and the cytotechnologist (§493.1481 to §493.1485).
Related page: Gynecologic Cytology Quality Assurance: 10% Rescreening, 5-Year Lookback, Cytologic-Histologic Correlation and Proficiency Testing (10% rescreening, 5-year lookback, cytologic-histologic correlation and proficiency testing) Related page: Cytology Quality Assurance Metrics, Test Validation and Quality Control (laboratory statistics, benchmarks, validation and automated screening) Related page: Cytology Laboratory Operations: Requisitions and Specimen Acceptance, Record and Slide Retention, Safety, and Billing and Coding (requisitions, specimen acceptance, retention, safety and coding) Related page: Medicolegal Issues and Communication of Cytology Results (reports, corrected reports and litigation) Related page: Cervical Cancer Screening, Specimen Collection and Quality Assurance in Cervical Cytology (cervical screening programs)
Structure of 42 CFR Part 493 for a cytology laboratory
| Subpart | Content relevant to cytology | Key sections |
|---|---|---|
| A, General provisions | Basis and scope; definitions; test complexity categories; certificate types | §493.1, §493.2, §493.5 |
| E, Accreditation | Deemed status through a CMS-approved accreditation organization | §493.551 to §493.575 |
| H and I, Proficiency testing | Gynecologic cytology proficiency testing of individuals | §493.853, §493.855, §493.945 |
| J, Facility administration | Retention of records, slides, blocks and tissue | §493.1105 |
| K, Quality system | General, preanalytic, analytic and postanalytic systems; the cytology standard | §493.1200 to §493.1299; §493.1274 |
| M, Personnel | Director, technical supervisor, cytology general supervisor, cytotechnologist | §493.1441 to §493.1495 |
| Q, Inspection | Inspection of certified and accredited laboratories | §493.1771 to §493.1780 |
Source: 42 CFR Part 493 (eCFR, current to 2 November 2026).
- Applicability to cytology. A laboratory that provides services in the subspecialty of cytology must meet §§493.1230 through 493.1256, §493.1274 and §§493.1281 through 493.1299 (42 CFR 493.1221).
- Place of examination. All cytology slide preparations must be evaluated on the premises of a laboratory certified to conduct testing in the subspecialty of cytology (42 CFR 493.1274(a)).
- Elements of §493.1274. The section covers the examination site (a), staining (b), control procedures including rescreening, correlation and annual statistics (c), workload limits (d), slide examination and reporting (e), record and slide retention (f), automated and semi-automated screening devices (g) and documentation (h) (42 CFR 493.1274).
Workload limits in 42 CFR 493.1274(d)
The absolute limit of 100 slides in 24 hours
- Daily maximum. The maximum number of slides examined by an individual in each 24-hour period does not exceed 100 slides (42 CFR 493.1274(d)(2)).
- Slide definition. The limit counts one patient specimen per slide. It includes gynecologic slides, nongynecologic slides or both (42 CFR 493.1274(d)(2)).
- All sites combined. The limit applies "irrespective of the site or laboratory." Slides examined for a second employer count toward the same 100-slide total (42 CFR 493.1274(d)(2)).
- Absolute maximum. The regulation states that the limit is an absolute maximum and must not be employed as an individual's performance target (42 CFR 493.1274(d)(2)).
- Workday. The maximum of 100 slides is examined in no less than an 8-hour workday (42 CFR 493.1274(d)(2)(i)).
Proration for less than 8 hours of slide examination
For individuals who examine slides for less than 8 hours, including full-time employees with other duties and part-time employees, an 8-hour period is used to prorate the number of slides (42 CFR 493.1274(d)(2)(ii)). The regulatory formula is:
Maximum slide volume = (number of hours examining slides × 100) ÷ 8
| Hours of slide examination in 24 hours | Maximum slides (prorated) |
|---|---|
| 8 | 100 |
| 7 | 87.5 |
| 6 | 75 |
| 5 | 62.5 |
| 4 | 50 |
| 2 | 25 |
Source: 42 CFR 493.1274(d)(2)(ii) (formula published at 68 FR 3703, 24 January 2003).
Counting rules that change the slide total
| Situation | Counting rule | Source |
|---|---|---|
| Nongynecologic liquid-based preparation with cells dispersed over one-half or less of the slide | May be counted as one-half slide | 42 CFR 493.1274(d)(2)(iii) |
| Technical supervisor who performs primary screening | Tissue pathology slides and previously examined cytology slides are excluded from the 100-slide limit | 42 CFR 493.1274(d)(2)(iv) |
| Gynecologic slide with field-of-view-only review on an FDA-approved semi-automated screening device | Counted as 0.5 slide | FDA 2010 workload communication |
| Gynecologic slide screened by the device with field-of-view review and full manual review | Counted as 1.5 slides | FDA 2010 workload communication |
| Gynecologic slide with full manual review only (conventional smear, or liquid-based slide screened without the device) | Counted as 1 slide; total not to exceed 100 slides in no less than an 8-hour day | FDA 2010 workload communication; 42 CFR 493.1274(d)(2) |
| Automated or semi-automated screening device | Manufacturer's instructions are followed for preanalytic, analytic and postanalytic phases, and subpart K applies | 42 CFR 493.1274(g) |
Records of slide counts and hours
- Laboratory records. The laboratory keeps records of the total number of slides examined by each individual in each 24-hour period and the number of hours spent examining slides, irrespective of the site or laboratory (42 CFR 493.1274(d)(3)).
- Documentation of each limit. Records are available to document the workload limit for each individual (42 CFR 493.1274(d)(4)).
- Personal records. The cytotechnologist documents the total slides examined or reviewed in the laboratory and for any other laboratory or employer in each 24-hour period, and the hours spent examining slides (42 CFR 493.1485(b) and (c)). The cytology general supervisor has the same documentation duty (42 CFR 493.1471(b)(3) and (4)).
- Technical supervisor as screener. A technical supervisor who screens slides documents the number screened in 24 hours and the hours devoted to screening (42 CFR 493.1451(c)(6)).
Workload assessment for each screener
Basis of the individual workload limit
- Responsibility. The technical supervisor establishes a maximum workload limit for each individual who performs primary screening (42 CFR 493.1274(d)(1); 42 CFR 493.1451(c)(2)).
- Performance evidence. The limit is based on the individual's performance, using the review of 10% of the cases interpreted as negative and the comparison of the individual's interpretations with the technical supervisor's confirmation of abnormal and nongynecologic slides (42 CFR 493.1274(d)(1)(i)).
- Frequency. Each individual's workload limit is reassessed at least every 6 months and adjusted when necessary (42 CFR 493.1274(d)(1)(ii); 42 CFR 493.1451(c)(3)).
- Statistical comparison. The laboratory evaluates the case reviews of each individual against the laboratory's overall statistical values and documents discrepancies, reasons for deviation and corrective actions (42 CFR 493.1274(c)(6)).
Evidence on screening workload and sensitivity
- ASC recommendations for image-assisted screening (2013). An American Society of Cytopathology task force judged that the FDA limit of 100 slides per day for image-assisted screening, with imaged-only slides counted as 0.5, risked reduced sensitivity. It recommended no more than 7 hours of Pap test screening in 24 hours and an average laboratory workload of no more than 70 slides per day by the 2010 FDA count. It also recommended full manual review of at least 15% of imaged slides or of twice the epithelial cell abnormality rate, whichever is greater (Elsheikh et al. 2013).
- Manual screening data. In a reanalysis of 3 prospective trials of automated devices, sites that restricted manual screening to under 6 hours per day, 50 or fewer slides per day and at least 6 minutes per slide had a relative sensitivity for automation of 0.81 for ASC-US or higher. Sites without these restrictions had a relative sensitivity of 1.07 (Renshaw and Elsheikh 2013).
- Practice survey. In the 2011 CAP survey of 2010 practice, most laboratories did not limit cytotechnologist screening workload during the work shift, and 32% used image-assisted screening devices (Crothers et al. 2016).
Personnel in the cytology laboratory
Qualifications of cytology personnel by position
| Position | Qualification in 42 CFR Part 493 | Section |
|---|---|---|
| Technical supervisor (route b) | MD or DO licensed in the state, certified in both anatomic and clinical pathology by the American Board of Pathology or the American Osteopathic Board of Pathology | §493.1449(b) |
| Technical supervisor for cytology (route e) | MD or DO licensed in the state, certified in anatomic pathology by the American Board of Pathology or the American Osteopathic Board of Pathology | §493.1449(e)(1) |
| Delegate of the cytology technical supervisor | Individual in the final year of full-time training leading to the required certification; the qualified technical supervisor remains ultimately responsible | §493.1449(e)(2) |
| Cytology general supervisor | Qualified as a technical supervisor under §493.1449(b) or (e), or a qualified cytotechnologist with at least 3 years of full-time (2,080 hours per year) experience as a cytotechnologist within the preceding 10 years | §493.1469 |
| Cytotechnologist | State license where required, and graduation from a CAAHEP-accredited school of cytotechnology or certification by an HHS-approved certifying agency; individuals qualified and serving as of 28 December 2024, continuously since then, remain qualified | §493.1483 |
Source: 42 CFR 493.1449, 493.1469 and 493.1483 (eCFR, current to 2 November 2026). The personnel sections were amended at 88 FR 90041–90044 (28 December 2023).
- Who may examine slides. Each person examining cytology slide preparations meets the cytotechnologist qualifications or is qualified as a technical supervisor under §493.1449(b) or (e) (42 CFR 493.1483).
- Sufficient staffing. The laboratory has a sufficient number of qualified cytotechnologists to perform the cytotechnologist functions (42 CFR 493.1481) and a cytology general supervisor (42 CFR 493.1467).
- Grandfathering of technical supervisors. An individual qualified and serving as a technical supervisor for high-complexity testing in a CLIA-certified laboratory as of 28 December 2024, continuously since then, is considered qualified (42 CFR 493.1449(j)).
Duties of the cytology technical supervisor
The technical supervisor in cytology, or the delegate under §493.1449(e)(2) (42 CFR 493.1451(c)):
- may perform the duties of the cytology general supervisor and of the cytotechnologist
- performs the functions in §493.1274(d) and (e), including confirmation of abnormal gynecologic slides and review of all nongynecologic preparations
- ensures that each individual examining gynecologic preparations participates in an HHS-approved cytology proficiency testing program and achieves a passing score
Slides that require technical supervisor review
| Specimen | Requirement | Section |
|---|---|---|
| Gynecologic slide interpreted as reactive or reparative changes | Confirmed by a technical supervisor | §493.1274(e)(1) |
| Gynecologic squamous abnormality: ASC-US, ASC-H, LSIL, HSIL, squamous cell carcinoma | Confirmed by a technical supervisor | §493.1274(e)(1)(i) |
| Gynecologic glandular abnormality: atypical cells (NOS, specified, or favor neoplastic), endocervical adenocarcinoma in situ, adenocarcinoma | Confirmed by a technical supervisor | §493.1274(e)(1)(ii) |
| Other malignant neoplasms | Confirmed by a technical supervisor | §493.1274(e)(1)(iii) |
| Every nongynecologic preparation | Reviewed by a technical supervisor | §493.1274(e)(3) |
| Report of any of the above | Signed, or electronically signed with authorization, to reflect technical supervisory review | §493.1274(e)(2) and (3) |
- Negative gynecologic slides. A gynecologic slide interpreted as negative by a qualified cytotechnologist does not require technical supervisor confirmation. These slides are the population from which the 10% review is drawn (42 CFR 493.1274(c)(1)).
- Who performs the 10% review. A technical supervisor qualified under §493.1449(b) or (e), a cytology general supervisor, or a cytotechnologist with the experience in §493.1469(b)(2) performs the review (42 CFR 493.1274(c)(1)(i)).
Duties of the cytology general supervisor and cytotechnologist
- Day-to-day oversight. The cytology general supervisor is responsible for day-to-day supervision or oversight of the laboratory operation and the personnel performing testing and reporting (42 CFR 493.1471(a)).
- Consultation. The general supervisor is accessible for on-site, telephone or electronic consultation to resolve technical problems under policies set by the technical supervisor (42 CFR 493.1471(b)(1)).
- Documentation of interpretations. The cytology general supervisor and each cytotechnologist document the interpretation of each gynecologic and nongynecologic case examined or reviewed (42 CFR 493.1471(b)(2); 42 CFR 493.1485).
- Delegation. The technical supervisor may perform the general supervisor's duties or delegate them to an individual qualified under §493.1469 (42 CFR 493.1471).
Competency assessment of testing personnel
- Written policy. The laboratory establishes and follows written policies and procedures to assess employee and consultant competency (42 CFR 493.1235).
- Six elements. Competency evaluation for high-complexity testing includes direct observation of routine test performance; monitoring of recording and reporting of results; review of worksheets, quality control, proficiency testing and maintenance records; direct observation of instrument maintenance and function checks; assessment by previously analyzed specimens, blind samples or external proficiency testing samples; and assessment of problem-solving skills (42 CFR 493.1451(b)(8)).
- Frequency. Performance is evaluated at least semiannually during the first year of patient testing and at least annually thereafter. A change in methodology or instrumentation requires reevaluation before patient results are reported (42 CFR 493.1451(b)(9)).
Remote review of digital cytology images
- Statutory premises rule. The CLIA statute (42 U.S.C. 263a(f)(4)(B)(vi)) and 42 CFR 493.1274(a) require cytology slide preparations to be evaluated on the premises of a laboratory certified in cytology (CMS QSO-23-15-CLIA, revised 23 September 2025).
- Enforcement discretion for other specialties. CMS continues to permit remote review of digital laboratory data, results and images without a separate certificate for the remote site when the primary site holds a certificate covering the specialty. A private residence may be a remote site (CMS QSO-23-15-CLIA, revised 23 September 2025). This discretion remains enforcement policy and is not regulation; the October 2026 proposed rule would codify it for specialties other than cytology (91 FR 64481).
- End of discretion for cytology. The revised memorandum discontinued, effective 23 March 2026 (6 months after 23 September 2025), the discretion that had allowed remote review of cytology digital slides. Since that date, a laboratory reviewing digital cytology images at a remote location needs a separate CLIA certificate for that location (CMS QSO-23-15-CLIA, revised 23 September 2025; 91 FR 64481).
- Physical slides. Physical slides, including cytology slides read with a microscope, cannot be read remotely under the primary location's certificate (CMS QSO-23-15-CLIA, revised 23 September 2025).
- Proposed rule of October 2026. A CMS proposed rule published on 8 October 2026 would define and codify "virtual access", meaning remote review of digital data, results, live imaging and digital images under the primary laboratory's certificate. The subspecialty of cytology is excluded. Under the proposal, individuals who examine cytology slides, digital images or digital data away from the primary laboratory would still need a separate CLIA certificate with the cytology subspecialty for that location. The rule would also allow digital images in gynecologic cytology proficiency testing. The comment period closes on 7 December 2026. The rule is proposed and not in effect (91 FR 64480–64482).
Related page: Rapid on-site evaluation, telecytology and core needle touch imprints (telecytology for rapid on-site evaluation)
CLIA certificates and inspection
| Certificate (§493.5(c)) | Basis | Inspection |
|---|---|---|
| Registration certificate | Enables moderate- or high-complexity testing until compliance is established by survey or through accreditation (§493.2) | Initial inspection before a certificate of compliance is issued (§493.1777(a)) |
| Certificate of compliance | Issued after an inspection finds compliance with all applicable condition-level requirements (§493.2) | Subsequent inspections on a biennial basis or at a frequency CMS determines (§493.1777(b)) |
| Certificate of accreditation | Issued on the basis of accreditation by a CMS-approved accreditation organization (§493.2) | Validation and complaint inspections by CMS at any time during hours of operation (§493.1780) |
| Certificate of waiver; certificate for provider-performed microscopy | Limited to waived tests (§493.15) or to the PPM procedures listed in §493.19(c) | Not applicable; neither certificate covers cytology or other high-complexity testing (§493.15; §493.19) |
- Cytology as high-complexity testing. The technical supervisor and cytotechnologist rules are written for laboratories performing high-complexity testing (42 CFR 493.1449; 42 CFR 493.1481).
- Deemed status. CMS may deem a laboratory to meet CLIA requirements through accreditation by an approved private nonprofit organization whose requirements are equal to or more stringent than the CLIA condition-level requirements (42 CFR 493.551(a)).
- Obligations of an accredited laboratory. The laboratory obtains a certificate of accreditation, pays the applicable fees, meets the proficiency testing requirements of subpart H, and authorizes release of its proficiency testing results to the accreditation organization and of unsuccessful results to CMS (42 CFR 493.551(b)).
- Loss of accreditation. After withdrawal or revocation of accreditation, the laboratory retains its certificate of accreditation for 45 days after notice or until the effective date of any CMS action, whichever is earlier (42 CFR 493.551(c)).
Accreditation organizations approved for cytology
| Accreditation organization | Approved for cytology (CMS list, September 2026) |
|---|---|
| Accreditation Commission for Health Care (ACHC) | Yes |
| American Association for Laboratory Accreditation (A2LA) | Yes |
| American Society for Histocompatibility and Immunogenetics (ASHI) | No; approved for histocompatibility and selected other specialties |
| Association for the Advancement of Blood & Biotherapies (AABB) | No; approved for blood bank, microbiology, immunology and related specialties |
| College of American Pathologists (CAP) | Yes |
| Commission on Laboratory Accreditation (COLA) | Yes |
| The Joint Commission (TJC) | Yes |
Source: CMS, Specialty/subspecialty information for approved accreditation organizations under CLIA, September 2026.
- CAP inspection cycle. CAP Laboratory Accreditation Program on-site inspections occur every 2 years, and the checklists are updated annually (CAP Laboratory Accreditation Program).
- Exempt states. A state licensure program approved by CMS can exempt state-licensed laboratories from CLIA program requirements (42 CFR 493.551(a)).
Errors in applying CLIA cytology workload and personnel rules
| Situation | Correct application | Source |
|---|---|---|
| A cytotechnologist screens 60 slides at a hospital and 50 at a second laboratory on the same day | 110 slides exceeds the 100-slide limit, which applies irrespective of site or laboratory | 42 CFR 493.1274(d)(2) |
| A part-time cytotechnologist screens for 4 hours and examines 70 slides | The prorated maximum for 4 hours is 50 slides | 42 CFR 493.1274(d)(2)(ii) |
| The laboratory sets 100 slides as the expected daily output | The limit must not be used as a performance target | 42 CFR 493.1274(d)(2) |
| Workload limits were last set 11 months earlier | Limits are reassessed at least every 6 months | 42 CFR 493.1274(d)(1)(ii) |
| A newly certified cytotechnologist performs the 10% negative review | The reviewer needs 3 years of full-time cytotechnologist experience within the preceding 10 years, or supervisor qualifications | 42 CFR 493.1274(c)(1)(i); 42 CFR 493.1469(b)(2) |
| A cytotechnologist signs out a negative bronchial washing | Every nongynecologic preparation is reviewed by a technical supervisor | 42 CFR 493.1274(e)(3) |
| A cytotechnologist screens glass slides at home with a microscope under the hospital certificate | A separate CLIA certificate is required for the home site | CMS QSO-23-15-CLIA, revised 23 September 2025; 42 CFR 493.1274(a) |
| A pathologist reviews digital cytology images from home under the hospital certificate on or after 23 March 2026 | A separate CLIA certificate is needed for the remote location | CMS QSO-23-15-CLIA, revised 23 September 2025 |
Gynecologic Cytology Quality Assurance: 10% Rescreening, 5-Year Lookback, Cytologic-Histologic Correlation and Proficiency Testing
Definition. Gynecologic cytology quality assurance in the United States rests on the control procedures of 42 CFR 493.1274(c) and on the proficiency testing rules of 42 CFR 493.855 and 493.945. The control program is a written program designed to detect errors in the performance of cytologic examinations and the reporting of results (42 CFR 493.1274(c)). Its required elements are prospective review of at least 10% of negative gynecologic cases before reporting, comparison of high-grade and malignant gynecologic reports with histopathology, review of prior negative specimens from the preceding 5 years for each patient with a current high-grade or malignant result, documentation of all rescreening, annual laboratory statistics and evaluation of each individual against the laboratory's values. Gynecologic cytology is the only cytology testing with federally regulated proficiency testing of individuals (42 CFR 493.853). The CAP Gynecologic Cytopathology Quality Consensus Conference, published in 2013, added consensus statements on good practice for each of these monitors (Tworek et al. 2013, background).
Related page: CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation (workload limits, personnel and accreditation) Related page: Cytology Quality Assurance Metrics, Test Validation and Quality Control (annual statistics, interpretive rates and benchmarks) Related page: Medicolegal Issues and Communication of Cytology Results (amended reports and litigation) Related page: Cervical Cancer Screening, Specimen Collection and Quality Assurance in Cervical Cytology (screening intervals and collection) Related page: The Bethesda System for Reporting Cervical Cytology (reporting categories)
Required gynecologic control procedures in 42 CFR 493.1274(c)
| Element | Requirement | Paragraph |
|---|---|---|
| Prospective review of negatives | Slides from at least 10% of gynecologic cases interpreted as negative for epithelial cell abnormalities and other malignant neoplasms, by individuals qualified under §493.1469 or §493.1483 | (c)(1) |
| Cytologic-histologic correlation | Comparison of clinical information with cytology reports, and comparison of every gynecologic report of HSIL, adenocarcinoma or other malignant neoplasm with the histopathology report if available; causes of discrepancies determined | (c)(2) |
| Retrospective review | For each patient with a current HSIL, adenocarcinoma or other malignant neoplasm, review of all normal or negative gynecologic specimens received within the previous 5 years, if available | (c)(3) |
| Documentation | Records of initial examinations and all rescreening results | (c)(4) |
| Annual statistics | Annual statistical evaluation of cases, specimens, diagnoses, histologic correlation, discrepancies and rescreening reclassifications | (c)(5) |
| Individual evaluation | Each individual's case reviews compared with the laboratory's overall statistical values, with documentation of discrepancies and corrective actions | (c)(6) |
Source: 42 CFR 493.1274(c) (eCFR, current to 2 November 2026).
Prospective review of 10% of negative gynecologic cases
Regulatory requirements of the 10% review
- Population and fraction. Slides from at least 10% of gynecologic cases interpreted as negative for epithelial cell abnormalities and other malignant neoplasms by individuals qualified under §493.1469 or §493.1483 are reviewed (42 CFR 493.1274(c)(1)).
- Reviewer. The review is performed by a technical supervisor qualified under §493.1449(b) or (e), a cytology general supervisor, or a cytotechnologist with at least 3 years of full-time experience within the preceding 10 years (42 CFR 493.1274(c)(1)(i); 42 CFR 493.1469(b)(2)).
- Selection. Cases are randomly selected from the total caseload. The selection includes negatives and cases from patients or groups of patients identified as having a higher than average probability of developing cervical cancer, based on available patient information (42 CFR 493.1274(c)(1)(ii)).
- Timing. The review of the selected cases is completed before patient results are reported (42 CFR 493.1274(c)(1)(iii)).
- Use in workload assessment. The 10% review is one of two performance measures on which the technical supervisor bases each screener's workload limit (42 CFR 493.1274(d)(1)(i)(A)).
Practice patterns and consensus statements on the 10% review
- Survey results. Among 541 responding laboratories in the CAP survey, more than 85% prospectively rescreened more than 10% of Pap tests interpreted as negative. Most (72%) included less than 20% high-risk cases, and most used several measures to define high risk (Brainard et al. 2013).
- Consensus statements. The working group stated that the number of Pap tests from high-risk patients should be maximized in prospective and retrospective rescreening. Unsatisfactory Pap tests should be included. All readily identifiable high-risk HPV-positive cases interpreted as negative for intraepithelial lesion or malignancy should be prospectively rescreened (Brainard et al. 2013).
- Feedback. Regular feedback to cytotechnologists and cytopathologists was recommended. Upgrades from negative to ASC-H should be monitored (Brainard et al. 2013).
Limits of the 10% review as a measure of screening sensitivity
- Low yield. The 10% review of negative slides and the 5-year lookback allow only a small fraction of errors to be detected and corrected, and do not measure the true sensitivity of screening (Renshaw 2003).
- Measured sensitivity. The sensitivity of the Pap smear in study settings ranges from 50% to 75% when a single consistent threshold is used, and up to 94% with automated-device-directed rescreening or thin-layer methods for HSIL at an ASC-US threshold (Renshaw 2002).
- Rapid prescreening. In a meta-analysis of 6 studies, rapid prescreening had a pooled sensitivity of 85.7% for high-grade lesions or worse and a pooled specificity of 96.8%. Sensitivity increased with screening duration and decreased with workload. Rapid prescreening detected 2.8% of all abnormal slides that full screening missed (Arbyn et al. 2003).
- Comparison with 10% review. Arbyn and colleagues had shown earlier that rapid review of negative slides is superior to full review of a random 10% sample (Arbyn et al. 2003).
- Use in the United States. Rapid prescreening was used as a quality assurance measure by 3.5% of laboratories in the 2011 CAP survey (Crothers et al. 2016).
| Method | Timing | Cases covered | Regulatory status in the United States | Source |
|---|---|---|---|---|
| Random 10% review with high-risk enrichment | Before reporting | At least 10% of negatives | Required | 42 CFR 493.1274(c)(1) |
| Rapid prescreening | Before full screening | All slides, by brief review | Optional; used by 3.5% of surveyed laboratories | Arbyn et al. 2003; Crothers et al. 2016 |
| Device-directed rescreening | After primary screening | Slides selected by an automated device | Optional; follows manufacturer's instructions | Wilbur et al. 2009; 42 CFR 493.1274(g) |
| Retrospective 5-year review | After a current high-grade or malignant result | All available prior negatives | Required | 42 CFR 493.1274(c)(3) |
Retrospective review of prior negatives: the 5-year lookback
Regulatory requirements of the 5-year lookback
- Trigger. A current gynecologic diagnosis of HSIL, adenocarcinoma or other malignant neoplasm in a patient (42 CFR 493.1274(c)(3)).
- Scope. All normal or negative gynecologic specimens received within the previous 5 years, if available in the laboratory on site or in storage (42 CFR 493.1274(c)(3)).
- Action on discrepancy. If significant discrepancies are found that will affect current patient care, the laboratory notifies the patient's physician and issues an amended report (42 CFR 493.1274(c)(3)).
- Annual statistic. The annual evaluation counts gynecologic cases in which any rescreen of a normal or negative specimen results in reclassification as LSIL, HSIL, adenocarcinoma or other malignant neoplasm (42 CFR 493.1274(c)(5)(vi)).
- Link to slide retention. Cytology slides are retained for at least 5 years from the date of examination (42 CFR 493.1105(a)(7)(i)(A)).
Practice patterns and outcomes of the 5-year lookback
- Window. Most laboratories (96.2%) retrospectively rescreened Pap tests from the preceding 5 years only (Brainard et al. 2013).
- Trigger in practice. In most laboratories (71.4%), only Pap test results of HSIL or worse prompted retrospective review. The consensus statement recommended that cervical biopsy results of CIN 2 or worse should also trigger retrospective rescreening (Brainard et al. 2013).
- Single-institution yield. At one academic laboratory from 2009 to 2019, 695 new HSIL-or-worse Pap tests had a prior negative Pap test. Review agreed with the negative diagnosis in 615. Sixty-one prior tests were reclassified: 3 as HSIL, 9 as ASC-H, 7 as AGC and 42 as ASC-US or LSIL. The major discrepancy rate (negative to HSIL or worse) was 3 of 695 (0.43%), and no case required an amended report (Nomani et al. 2021).
- Amended reports. The need to issue amended reports as a consequence of the lookback provision is rare (Frable 2007).
Cytologic-histologic correlation in gynecologic cytology
Regulatory requirements of gynecologic cytologic-histologic correlation
- Which reports. All gynecologic cytology reports with a diagnosis of HSIL, adenocarcinoma or other malignant neoplasm are compared with the histopathology report, if available in the laboratory on site or in storage (42 CFR 493.1274(c)(2)).
- Clinical information. Clinical information, when available, is compared with cytology reports (42 CFR 493.1274(c)(2)).
- Discrepancies. The laboratory determines the causes of any discrepancies (42 CFR 493.1274(c)(2)).
- Annual counts. The annual statistics include the number of HSIL, adenocarcinoma and other malignant cases with histology available for comparison, and the number of discrepant cases (42 CFR 493.1274(c)(5)(iv) and (v)).
Benchmarks for gynecologic cytologic-histologic correlation
| Measure | Value | Source |
|---|---|---|
| Paired cytology and cervical biopsy specimens | 22,439 pairs in 348 laboratories | Jones and Novis 1996 |
| Sensitivity of cervicovaginal cytology | 89.4% | Jones and Novis 1996 |
| Specificity | 64.8% | Jones and Novis 1996 |
| Positive predictive value of an abnormal cytology result | 88.9% | Jones and Novis 1996 |
| Main cause of discrepancies | Sampling error in the cytology or the biopsy | Jones and Novis 1996 |
| Effect of providing the cytology report to the surgical pathologist | Improved sensitivity | Jones and Novis 1996 |
- Timing of the cytology specimen. Cytology obtained at the time of biopsy had lower sensitivity and higher specificity than cytology obtained before the biopsy (Jones and Novis 1996).
- Consensus on correlation. Correlation may be performed retrospectively, at initial case review, or both. At minimum, all available slides are reviewed for an HSIL Pap test with negative biopsies. The preferred monitor for correlation is the positive predictive value of the Pap test (Crothers et al. 2013).
- Purpose. Laboratories should design correlation programs to explore existing or perceived quality deficiencies (Crothers et al. 2013).
Cytologic-histologic correlation in nongynecologic cytology
- Error frequency. A consortium of laboratories that benchmarked error frequencies through cytologic-histologic correlation found an aggregate nongynecologic error frequency of 10.8% (Raab 2006).
- Regulatory basis. The §493.1274(c)(2) correlation requirement is written for gynecologic reports. Nongynecologic correlation falls under the general requirement for ongoing monitoring, assessment and correction of problems in the analytic and postanalytic systems (42 CFR 493.1289; 42 CFR 493.1299).
Gynecologic cytology proficiency testing
Structure of gynecologic proficiency testing events in 42 CFR 493.855
| Event | Test set | Time allowed | Passing score | Consequence of failure |
|---|---|---|---|---|
| Annual test | 10 slides | 2 hours | At least 90% | Retest scheduled not more than 45 days after receipt of the failure notice |
| Second test | 10 slides | 2 hours | At least 90% | Documented remedial training and education in the area of failure; all gynecologic slides examined after the failure notice are reexamined until a 20-slide test is passed |
| Third test | 20 slides | 4 hours | At least 90% | Gynecologic slide examination stops immediately; at least 35 hours of documented, formally structured continuing education in gynecologic cytopathology before retesting with a 20-slide set |
Source: 42 CFR 493.855(b) (eCFR, current to 2 November 2026).
- Annual on-site event. Each individual examining gynecologic preparations is tested at least once per year. An announced or unannounced on-site testing event is held in each laboratory at least once a year, with at least 30 days' notice for announced events (42 CFR 493.855(a)).
- Unexcused absence. Unexcused failure to appear for a retest results in test failure with the corresponding remediation (42 CFR 493.855(b)).
- Laboratory sanctions. If a laboratory fails to ensure testing, retesting or remedial action, CMS initiates intermediate sanctions or limits the laboratory's certificate to exclude gynecologic cytology, and may suspend Medicare and Medicaid payments for gynecologic cytology (42 CFR 493.855(c)).
- Approved programs. The College of American Pathologists and the American Society for Clinical Pathology provide the approved gynecologic cytology proficiency testing programs, and both use a proctor to monitor glass-slide testing events (CMS, Proficiency testing program requirements: general and cytology; 91 FR 64484).
Test sets and reference diagnoses in 42 CFR 493.945
- Validation of slides. Every slide requires 100% consensus among at least 3 physicians certified in anatomic pathology. Premalignant and malignant slides also require confirmation by tissue biopsy (42 CFR 493.945(b)(1)).
- Content. Each test set includes at least one slide from each of the 4 response categories (42 CFR 493.945(a)(1)).
- Source of slides. Programs may obtain slides from laboratories that have retained them for the required period, or as loans with documentation that keeps them retrievable (42 CFR 493.945(a)(1)).
- Retesting schedule. Programs provide an initial retest within 45 days after notification of failure and later retests within 45 days after completion of remedial action (42 CFR 493.945(a)(2)).
- Prescreened sets for pathologists. A technical supervisor who routinely interprets gynecologic slides only after cytotechnologist examination may be tested with a set screened by a cytotechnologist in the same laboratory. A technical supervisor who screens unexamined slides is tested with an unscreened set (42 CFR 493.945(b)(2)).
| Category | Diagnoses included |
|---|---|
| A | Unsatisfactory for diagnosis: scant cellularity, air drying, obscuring material |
| B | Normal or benign changes: negative; infection other than HPV; reactive and reparative changes |
| C | LSIL: HPV-associated changes; mild dysplasia/CIN 1 |
| D | High-grade lesion and carcinoma: HSIL (CIN 2, CIN 3/carcinoma in situ), squamous cell carcinoma, adenocarcinoma and other malignant neoplasms |
Source: 42 CFR 493.945(b)(3)(ii)(A).
Scoring grids for a 10-slide gynecologic proficiency test set
Points for each slide by correct category (rows) and examinee response (columns). A slide scores a maximum of 10 points and a minimum of −5 points.
| Correct category | Technical supervisor: A / B / C / D | Cytotechnologist: A / B / C / D |
|---|---|---|
| A | 10 / 0 / 0 / 0 | 10 / 0 / 5 / 5 |
| B | 5 / 10 / 0 / 0 | 5 / 10 / 5 / 5 |
| C | 5 / 0 / 10 / 5 | 5 / 0 / 10 / 10 |
| D | 0 / −5 / 5 / 10 | 0 / −5 / 10 / 10 |
Source: 42 CFR 493.945(b)(3)(ii)(C) and (D). The score for the event is the sum of slide points divided by the total possible points, multiplied by 100 (42 CFR 493.945(b)(3)(ii)(B)).
- Twenty-slide sets. Correct responses earn 5 points and the penalty for calling a category D slide normal is −10 points (42 CFR 493.945(b)(3)(ii)(E)).
- Automatic failure. On a 10-slide set, one category D slide called category B gives −5 of a possible 100 points. The maximum score is then 85%, below the 90% pass mark (42 CFR 493.945(b)(3)(ii)(B) to (D)).
- Grading asymmetry. A cytotechnologist who places an LSIL slide in category D, or an HSIL-or-worse slide in category C, receives the full 10 points. A technical supervisor receives 5 points for either response. A cytotechnologist who calls a category A or B slide abnormal receives 5 points, and a technical supervisor receives 0 (42 CFR 493.945(b)(3)(ii)(C) and (D)).
Performance in the CAP gynecologic proficiency test
| Participant group (2006–2009) | Initial failure rate | Most common error type | Source |
|---|---|---|---|
| Cytotechnologists | 3.4% (614 of 18,264) | Automatic failures (75.7% of errors) | Ducatman et al. 2011 |
| Secondary pathologists (slides prescreened by cytotechnologists) | 4.2% (728 of 17,346) | False-positive responses (55.6% of errors) | Ducatman et al. 2011 |
| Primary screening pathologists | 13.7% (194 of 1,419) | False-positive responses (63.9% of errors) | Ducatman et al. 2011 |
- False-positive responses. Among negative reference slides, reparative changes were mistaken for HSIL or worse in 4.7% of responses and atrophic vaginitis in 1.8%. During proficiency testing, false-positive rates rose for negative and herpes simplex virus slides (Crothers et al. 2014).
- Consensus on use of results. Two-thirds of laboratories reported an individual with an unsuccessful score. The consensus statements recommended monitoring pass-fail rates globally and for each individual, and prescreening of test slides by cytotechnologists for pathologists who are not primary screeners. Remedial action was not required for a passed but imperfect test or before retesting after a first failure (Howell et al. 2013).
- Proposed digital testing. A CMS proposed rule of 8 October 2026 would permit digital images of the test slides in gynecologic cytology proficiency testing. Approved programs would also need a system to monitor the integrity of testing. The proposed text keeps the 10-slide and 20-slide structure, the 2-hour and 4-hour limits, the 90% pass mark and the 35 hours of continuing education. The comment period closes on 7 December 2026, and the current glass-slide rules remain in force (91 FR 64483–64484, 64523–64524).
Nongynecologic proficiency testing and interlaboratory comparison
- No federally regulated program. For proficiency testing, the specialty of pathology includes the subspecialty of cytology limited to gynecologic examinations (42 CFR 493.853).
- Twice-yearly accuracy verification. At least twice annually, the laboratory verifies the accuracy of any test it performs that is not included in subpart I (42 CFR 493.1236(c)(1)). Nongynecologic cytology falls under this requirement because subpart I lists only gynecologic cytology.
- Documentation. All proficiency testing evaluation and verification activities are documented (42 CFR 493.1236(d)).
- Educational programs. Educational interlaboratory comparison programs, such as the CAP Interlaboratory Comparison Program in Gynecologic Cytopathology, are distinct from regulated proficiency testing (Crothers et al. 2014).
Errors in applying gynecologic quality assurance rules
| Situation | Correct application | Source |
|---|---|---|
| The 10% review is performed after the reports are issued | The review of selected cases is completed before reporting | 42 CFR 493.1274(c)(1)(iii) |
| The 10% sample excludes high-risk patients | Selection is random and includes patients at higher than average risk | 42 CFR 493.1274(c)(1)(ii) |
| Lookback triggered by a current LSIL | The trigger is a current HSIL, adenocarcinoma or other malignant neoplasm | 42 CFR 493.1274(c)(3) |
| Lookback of negatives received 7 years earlier | The window is the previous 5 years | 42 CFR 493.1274(c)(3) |
| Every lookback reclassification leads to an amended report | An amended report and physician notification are required for significant discrepancies that will affect current patient care | 42 CFR 493.1274(c)(3) |
| A pathologist who passed with 90% is placed on remediation | Remediation is not required for a passed but imperfect test | Howell et al. 2013 |
| A laboratory enrolls in a gynecologic program for nongynecologic cytology | Nongynecologic accuracy is verified at least twice annually under §493.1236(c) | 42 CFR 493.853; 42 CFR 493.1236(c) |
Cytology Quality Assurance Metrics, Test Validation and Quality Control
Definition. Quality assurance metrics in cytology are the counts, rates and ratios that a laboratory collects to monitor diagnostic performance, timeliness and test-system performance. Federal rules require an annual statistical evaluation of cytology cases and an evaluation of each individual against the laboratory's overall values (42 CFR 493.1274(c)(5) and (c)(6)). Laboratories compare their reporting rates with national benchmarks from CAP surveys (Davey et al. 2004; Eversole et al. 2010). The analytic side of quality control covers verification and establishment of performance specifications before patient testing (42 CFR 493.1253), maintenance and function checks of instruments (42 CFR 493.1254), control procedures for stains (42 CFR 493.1256(e)), the staining rules specific to cytology (42 CFR 493.1274(b)) and the use of automated and semi-automated screening devices (42 CFR 493.1274(g)).
Related page: CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation (workload limits and personnel) Related page: Gynecologic Cytology Quality Assurance: 10% Rescreening, 5-Year Lookback, Cytologic-Histologic Correlation and Proficiency Testing (10% review, lookback, correlation and proficiency testing) Related page: Cytology Laboratory Operations: Requisitions and Specimen Acceptance, Record and Slide Retention, Safety, and Billing and Coding (requisitions, retention and safety) Related page: Stains in Cytology (Papanicolaou and Romanowsky staining methods) Related page: Immunohistochemistry on Cytology Specimens (immunocytochemistry on cytology preparations) Related page: Digital Image Analysis and Artificial Intelligence in Cytology (digital and artificial intelligence systems)
Annual statistical evaluation required by 42 CFR 493.1274(c)(5)
| Required count | Purpose in quality assurance |
|---|---|
| Cytology cases examined | Laboratory volume |
| Specimens processed by specimen type | Volume by gynecologic and nongynecologic source |
| Patient cases reported by diagnosis, including unsatisfactory | Interpretive rates by category |
| Gynecologic HSIL, adenocarcinoma or other malignant cases with histology available | Denominator for cytologic-histologic correlation |
| Gynecologic cases with discrepant cytology and histology | Correlation discrepancies |
| Gynecologic cases in which a rescreen of a negative specimen led to reclassification as LSIL, HSIL, adenocarcinoma or other malignant neoplasm | Yield of the 10% review and the lookback |
Source: 42 CFR 493.1274(c)(5)(i) to (vi).
- Individual comparison. The laboratory evaluates the case reviews of each individual examining slides against the laboratory's overall statistical values. It documents discrepancies, the reasons for deviation and, if appropriate, the corrective actions taken (42 CFR 493.1274(c)(6)).
- Use in workload limits. These individual evaluations inform the workload limit that the technical supervisor sets and reassesses at least every 6 months (42 CFR 493.1274(d)(1)).
Consensus statements on cytology quality metrics
- Interpretive rates. The consensus statement judged monitoring of interpretive rates for all Bethesda System categories potentially useful, and most useful when rates are tracked for each cytotechnologist and compared with the entire laboratory (Clary et al. 2013).
- Cytotechnologist-pathologist concordance. Laboratories determine which level of discrepancy between cytotechnologist and pathologist interpretations of Pap tests is important to track, and formalize procedures to adjudicate discrepant interpretations (Clary et al. 2013).
- Comparison practices. In the CAP survey, 81.1% of laboratories compared individual cytotechnologist metrics with laboratory metrics, and 59.6% did so for pathologists (Tworek et al. 2013).
- Detection of variance. The most common methods for recognizing variance were identification of outliers in the data and user-defined action limits. The most common response was a search for the cause, followed by a focused review (Tworek et al. 2013).
- Scope of monitoring. Quality metrics are monitored for the laboratory as a whole and, in selected cases, for individual pathologists and cytotechnologists. Results are shared with individuals, newly hired primary screeners are monitored, and low-volume methods such as conventional Pap tests receive additional oversight (Tworek et al. 2013).
- HPV-positive rate of atypical squamous cells. More than half of laboratories (53.3%) monitored the HPV-positive rate in Pap tests with ASC-US. The consensus statement called this rate a valuable broad measure of laboratory quality (Booth et al. 2013).
- HPV testing and discrepancies. Laboratories should not order HPV testing to resolve diagnostic discrepancies. Low-risk HPV testing is not appropriate for any clinical circumstance in gynecologic cytology (Booth et al. 2013).
National benchmarks for Pap test reporting rates
| Measure | 1996 survey | 2003 survey | 2006 survey | Source |
|---|---|---|---|---|
| LSIL, median rate | 1.6% | 2.1% | 2.5% (2.9% for liquid-based preparations) | Davey et al. 2004; Eversole et al. 2010 |
| HSIL, median rate | Similar to 2003 | 0.5% | 0.5% | Davey et al. 2004; Eversole et al. 2010 |
| ASC-US, median rate | Similar to 2003 | 3.9% | 4.3% | Davey et al. 2004; Eversole et al. 2010 |
| ASC to SIL-and-carcinoma ratio, median | 2.0 | 1.4 | 1.5 | Davey et al. 2004; Eversole et al. 2010 |
| Laboratories using Bethesda 2001 terminology | Not applicable (survey preceded Bethesda 2001) | 85.5% | 97.8% | Davey et al. 2004; Eversole et al. 2010 |
- Survey populations. The 2003 survey drew 759 responses from 1,751 laboratories in the CAP Interlaboratory Comparison Program in Cervicovaginal Cytology (Davey et al. 2004). The 2006 survey drew 679 responses from 1,621 laboratories (42%) (Eversole et al. 2010).
- Effect of preparation type. Liquid-based preparations had higher median rates of squamous abnormalities than conventional smears in both surveys (Davey et al. 2004; Eversole et al. 2010). The 2003 survey also found lower median ASC to SIL ratios with liquid-based preparations (Davey et al. 2004).
- ASC-H. The median ASC-H rate in 2003 was 0.2% (Davey et al. 2004).
- Knowledge of HPV results. In 2003, almost half (47%) of laboratories did not know the percentage of positive HPV results in patients with ASC (Davey et al. 2004).
- Interpretation of the ratio. The ASC to SIL ratio, (ASC-US + ASC-H) ÷ (LSIL + HSIL), compares equivocal interpretations with definitive squamous lesions. A laboratory or individual ratio well above the benchmark median indicates a relative excess of ASC interpretations and leads to focused review (Davey et al. 2004; Tworek et al. 2013).
Turnaround time in cytology
- Nongynecologic benchmark. In a CAP Q-Probes study of 16,950 nongynecologic cases in 180 laboratories, half of the laboratories had mean receipt-to-report turnaround times of 1.6 calendar days or less and completed 90% of cases within 3.0 calendar days. Ten percent of participants had mean turnaround times above 3.2 days and needed 6.0 or more days to report 90% of cases (Jones and Novis 2001).
- Factors associated with longer turnaround. Fluid and FNA specimens, atypical, suspicious or nondiagnostic diagnoses, screening by cytotechnology students, calls to physician offices for information, retrieval of prior material, and preparation of cell blocks or special stains were associated with longer turnaround times (Jones and Novis 2001).
- Gynecologic turnaround. The consensus statement recommends monitoring turnaround time in gynecologic cytology. Each laboratory decides how to measure and use it internally (Clary et al. 2013).
- Regulatory duty for delays. When the laboratory cannot report patient results within its established time frames, it determines the need to notify the appropriate individuals of the delay, based on the urgency of the test (42 CFR 493.1291(h)).
- Start point. The laboratory documents the date and time it receives each specimen, which provides the start point for receipt-to-report turnaround (42 CFR 493.1242(b)).
Verification and establishment of performance specifications
Performance specifications required by 42 CFR 493.1253
| Test system | Performance characteristics required before patient testing |
|---|---|
| Unmodified FDA-cleared or approved test system (verification) | Accuracy, precision and reportable range comparable to the manufacturer's; manufacturer's reference intervals verified as appropriate for the patient population |
| Modified FDA-cleared or approved system, test system not subject to FDA clearance, in-house method or textbook procedure, or system without manufacturer specifications (establishment) | Accuracy, precision, analytical sensitivity, analytical specificity including interfering substances, reportable range, reference intervals and any other characteristic required for test performance |
Source: 42 CFR 493.1253(b)(1) and (b)(2).
- Calibration and controls. The laboratory determines calibration and control procedures from the verified or established performance specifications (42 CFR 493.1253(b)(3)).
- Documentation. All activities are documented (42 CFR 493.1253(c)).
- Systems in use before 2003. Laboratories were not required to verify or establish performance specifications for test systems used before 24 April 2003 (42 CFR 493.1253(a)).
- Multiple methods or sites. A laboratory that performs the same test by different methods, instruments or sites evaluates the relationship between results twice a year (42 CFR 493.1281(a)).
Validation of immunohistochemistry on cytology specimens
- Guideline. The CAP updated its guideline on analytic validation of immunohistochemical assays in 2024. The update contains 2 strong recommendations, 1 conditional recommendation and 12 good practice statements, including statements for immunohistochemistry on cytology specimens (Goldsmith et al. 2024).
- Specimens in alternative fixatives. For cytology specimens fixed differently from the tissues used for the original validation, laboratories perform separate validations with a minimum of 10 positive and 10 negative cases (CAP guideline summary; Goldsmith et al. 2024).
- Reason. The literature has shown variable sensitivity of immunohistochemical assays performed on specimens collected in the fixatives that cytology laboratories often use (CAP guideline summary).
- Scope. The CAP states that the new cytology statements are not intended to mandate revalidation of all immunohistochemical assays on cytology specimens (CAP guideline summary).
- Concordance. The update sets the concordance requirement at 90% for all immunohistochemical assays (CAP guideline summary).
- Controls at each use. Fluorescent and immunohistochemical stains are checked for positive and negative reactivity each time of use (42 CFR 493.1256(e)(3)).
Validation of telecytology for rapid on-site evaluation
- ASC recommendations (2024). Validation of telecytology for rapid on-site evaluation includes testing of all hardware and software separately and together, training of all participants with regular competency evaluations, and a structured approach with retrospective slides of known diagnosis for validation and prospective cases for verification (Lin et al. 2024).
- Discrepancy monitoring. Benchmarks for discrepancy rates between preliminary and final diagnoses are established and monitored. Discrepancies that downgrade malignant cases to benign receive particular attention (Lin et al. 2024).
Automated and semi-automated screening devices in gynecologic cytology
- Regulatory rule. A laboratory using automated or semi-automated screening devices follows the manufacturer's instructions for the preanalytic, analytic and postanalytic phases and meets the applicable requirements of subpart K (42 CFR 493.1274(g)).
- Workload counting. Under the 2010 FDA counting method for semi-automated gynecologic screening devices, a slide with field-of-view review only counts as 0.5 slide. A slide with field-of-view review and full manual review counts as 1.5 slides. A slide with full manual review only counts as 1 slide. The total may not exceed the CLIA maximum of 100 slides in no less than an 8-hour day (FDA 2010 workload communication; 42 CFR 493.1274(d)(2)). The method was written for the ThinPrep Imaging System and the FocalPoint GS Imaging System (FDA 2010 workload communication).
- Adoption. In 2010, 32% of surveyed laboratories used image-assisted screening devices (Crothers et al. 2016). In its October 2026 proposed rule, CMS estimated that about 25% of the 3,229 CLIA-certified laboratories performing cytology (807 laboratories) had adopted digital images as their primary screening method (91 FR 64507, 64518; proposed rule).
| System | Evidence at approval or validation | Source |
|---|---|---|
| ThinPrep Imaging System | Trial of 10,742 specimens at 4 sites: greater sensitivity than manual screening for ASC-US or higher, equivalent for LSIL or higher and HSIL or higher, higher specificity for HSIL or higher; daily screening rates doubled | Biscotti et al. 2005 |
| BD FocalPoint GS Imaging System | Masked 2-arm trial of 12,313 SurePath slides: sensitivity for HSIL or higher increased by 19.6% and for LSIL or higher by 9.8%, with small decreases in specificity | Wilbur et al. 2009 |
| ThinPrep Imaging System compared with FocalPoint GS | No significant difference in relative sensitivity across 3 prospective trials | Renshaw and Elsheikh 2013 |
| Genius Digital Diagnostics System with the Genius Cervical AI algorithm | FDA De Novo request granted 31 January 2024 (DEN210035; regulation 21 CFR 864.3900; product code QYV) | FDA De Novo database |
| Genius Digital Diagnostics System, clinical validation | 1,748 Pap tests: 98.5% concordance with ThinPrep Imaging System interpretation against a 95% validation threshold; most discordances were unsatisfactory versus negative | Underwood et al. 2026 |
- Quality control of artificial intelligence-assisted screening. One 2026 study rescanned and reinterpreted 497 archival ThinPrep slides on the Genius system after a 14-month washout. Kappa values between serial reads by the same pathologists ranged from 0.51 to 0.559. The authors proposed periodic rescanning and reanalysis of randomly selected slides as a quality control method once regulatory guidance is updated (Harinath et al. 2026).
Quality control of instruments, reagents and environmental conditions
- Storage and operating conditions. The laboratory defines, monitors and documents the conditions essential for reagent and specimen storage and test system operation, including water quality, temperature, humidity and protection from electrical fluctuation where applicable (42 CFR 493.1252(b)).
- Labeling. Reagents, solutions, control materials and supplies are labeled with identity and, when significant, concentration, storage requirements, preparation and expiration dates, and other information needed for proper use (42 CFR 493.1252(c)).
- Expired or deteriorated materials. Reagents and supplies are not used after their expiration date or when they have deteriorated or are of substandard quality (42 CFR 493.1252(d)).
- Maintenance and function checks. For unmodified manufacturer's equipment, maintenance and function checks are performed and documented at least as often as the manufacturer specifies, and function checks are within the manufacturer's limits before patient testing. For in-house or modified equipment, the laboratory establishes its own protocols (42 CFR 493.1254).
- Corrective action. The laboratory documents corrective actions when test systems fail to meet performance specifications or when control results fail, and evaluates all patient results since the last acceptable run (42 CFR 493.1282(b)).
Stain quality control in cytology
| Requirement | Rule | Source |
|---|---|---|
| Gynecologic stain | All gynecologic slide preparations are stained by a Papanicolaou or modified Papanicolaou method | 42 CFR 493.1274(b)(1) |
| Cross-contamination between specimen types | Effective measures prevent cross-contamination between gynecologic and nongynecologic specimens during staining | 42 CFR 493.1274(b)(2) |
| High-risk nongynecologic specimens | Specimens with a high potential for cross-contamination are stained separately from other nongynecologic specimens, and the stains are filtered or changed after staining | 42 CFR 493.1274(b)(3) |
| Staining materials | Each day of use, staining materials are tested for intended reactivity, with positive and negative controls as appropriate, unless subpart K specifies otherwise | 42 CFR 493.1256(e)(2) |
| New lots and shipments | Each batch, lot number and shipment of stains is checked when prepared or opened | 42 CFR 493.1256(e)(1) |
| Acceptability before reporting | Control results meet the laboratory's and manufacturer's criteria before patient results are reported | 42 CFR 493.1256(f) |
- Written procedures. The laboratory has and follows written policies and procedures for each staining requirement that applies to its work (42 CFR 493.1274(b)).
- Documentation. The laboratory documents all control procedures performed under §493.1274 (42 CFR 493.1274(h)).
Errors in applying cytology quality metrics and validation rules
| Situation | Correct application | Source |
|---|---|---|
| The laboratory reports only its total case count in the annual evaluation | The evaluation includes cases by diagnosis, specimens by type, correlation counts, discrepancies and rescreening reclassifications | 42 CFR 493.1274(c)(5) |
| A pathologist's ASC-US rate is reviewed without reference to laboratory values | Individual case reviews are compared with the laboratory's overall statistics | 42 CFR 493.1274(c)(6) |
| HPV testing is ordered to settle a cytotechnologist-pathologist disagreement | HPV testing is not used to resolve diagnostic discrepancies | Booth et al. 2013 |
| A modified FDA-cleared assay is introduced after verification of accuracy and precision only | A modified system requires establishment of all applicable performance characteristics | 42 CFR 493.1253(b)(2) |
| An immunostain validated on formalin-fixed tissue is applied to alcohol-fixed cell blocks without further study | Separate validation with at least 10 positive and 10 negative cases | Goldsmith et al. 2024; CAP guideline summary |
| A field-of-view-only imaged slide is counted as 1 slide | Counted as 0.5 slide under the 2010 FDA counting method | FDA 2010 workload communication |
Cytology Laboratory Operations: Requisitions and Specimen Acceptance, Record and Slide Retention, Safety, and Billing and Coding
Definition. Cytology laboratory operations are the preanalytic, administrative and safety functions that surround slide interpretation. Federal laboratory rules govern the test request (42 CFR 493.1241), specimen submission, handling and referral (42 CFR 493.1242), test records (42 CFR 493.1283) and the retention of records, slides and blocks (42 CFR 493.1105). Occupational Safety and Health Administration (OSHA) standards set exposure limits for formaldehyde (29 CFR 1910.1048) and xylene (29 CFR 1910.1000). Medicare coding of cytopathology specimens follows the CPT code families for each preparation type and the National Correct Coding Initiative (NCCI) policy manual (CMS NCCI Policy Manual, Chapter X, revised 1 January 2026). Medicare coverage of screening Pap tests follows National Coverage Determination 210.2 and the Medicare Claims Processing Manual (CMS NCD 210.2; Medicare Claims Processing Manual, Chapter 18, §30).
Related page: CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation (personnel, workload and accreditation) Related page: Gynecologic Cytology Quality Assurance: 10% Rescreening, 5-Year Lookback, Cytologic-Histologic Correlation and Proficiency Testing (lookback review and slide loans to proficiency testing programs) Related page: Medicolegal Issues and Communication of Cytology Results (report content and release of slides in litigation) Related page: Cytology Specimen Types and Triage (specimen collection and triage) Related page: Rapid on-site evaluation, telecytology and core needle touch imprints (rapid on-site evaluation and its coding, 88172 and 88177)
Test requisitions in cytology
Required content of the requisition (42 CFR 493.1241)
| Element solicited by the requisition | Paragraph |
|---|---|
| Name and address or other identifier of the authorized person requesting the test, or of the referring laboratory, with a contact person for urgent results where applicable | (c)(1) |
| Patient name or unique patient identifier | (c)(2) |
| Sex and age or date of birth | (c)(3) |
| Test or tests to be performed | (c)(4) |
| Source of the specimen, when appropriate | (c)(5) |
| Date and, if appropriate, time of collection | (c)(6) |
| For Pap smears: last menstrual period, and whether the patient had a previous abnormal report, treatment or biopsy | (c)(7) |
| Any additional information needed for accurate and timely testing, reporting and interpretation | (c)(8) |
Source: 42 CFR 493.1241(c).
- Authorized request. The laboratory has a written or electronic request for patient testing from an authorized person (42 CFR 493.1241(a)).
- Oral requests. The laboratory may accept an oral request if it solicits written or electronic authorization within 30 days and keeps the authorization or documentation of its efforts to obtain it (42 CFR 493.1241(b)).
- Medical record as requisition. The patient's chart or medical record may serve as the requisition, provided it is available to the laboratory at the time of testing and to CMS on request (42 CFR 493.1241(d)).
- Transcription. Requisition information entered into a laboratory information system is transcribed or entered accurately (42 CFR 493.1241(e)).
Specimen submission, acceptance and rejection
Specimen receipt, referral and test records
- Written policies. The laboratory establishes and follows written policies and procedures, if applicable, for patient preparation, specimen collection, labeling, storage and preservation, transportation, processing, acceptability and rejection, and referral. Labels carry the patient name or unique identifier and, when appropriate, the specimen source (42 CFR 493.1242(a)).
- Receipt. The laboratory documents the date and time it receives a specimen (42 CFR 493.1242(b)).
- Referral. The laboratory refers a specimen only to a CLIA-certified laboratory or one meeting equivalent requirements as determined by CMS (42 CFR 493.1242(c)).
- Test records. The record system includes positive identification of the specimen, the date and time of receipt, the condition and disposition of specimens that do not meet acceptability criteria, and the records and dates of all testing with the identity of the personnel who performed it (42 CFR 493.1283(a)).
- Report of an unacceptable specimen. The test report includes any information on the condition and disposition of specimens that do not meet the laboratory's criteria for acceptability (42 CFR 493.1291(c)(7)).
- Unsatisfactory specimens. A specimen processed but unsatisfactory for interpretation is identified and reported as unsatisfactory (42 CFR 493.1274(e)(4)).
- Preanalytic quality assessment. The laboratory monitors, assesses and corrects problems in test requests and specimen handling, reviews the effectiveness of corrective actions, and documents these activities (42 CFR 493.1249).
Retention of records, slides and blocks
Minimum retention periods in 42 CFR 493.1105
| Item | Minimum retention | Paragraph |
|---|---|---|
| Test requisitions and authorizations, including a chart used as the requisition | 2 years | (a)(1) |
| Test procedures | 2 years after the procedure is discontinued; each procedure records its dates of initial use and discontinuance | (a)(2) |
| Quality control and patient test records, instrument printouts and analytic systems records | 2 years | (a)(3) |
| Records of performance specifications established or verified | For the period the test system is in use, and no less than 2 years | (a)(3)(i) |
| Proficiency testing records | 2 years | (a)(4) |
| Quality system assessment records | 2 years | (a)(5) |
| Test reports (final, preliminary and corrected) | 2 years after the date of reporting | (a)(6) |
| Pathology test reports | 10 years after the date of reporting | (a)(6)(ii) |
| Cytology slide preparations | 5 years from the date of examination | (a)(7)(i)(A) |
| Histopathology slides | 10 years from the date of examination | (a)(7)(i)(B) |
| Pathology specimen blocks (a paraffin cell block is a pathology specimen block) | 2 years from the date of examination | (a)(7)(ii) |
| Remnants of tissue for pathology examination | Until a diagnosis is made on the specimen | (a)(7)(iii) |
Source: 42 CFR 493.1105(a) (eCFR, current to 2 November 2026). The table gives CLIA minimum periods; accreditation organizations may require longer retention.
- Laboratory closure. A laboratory that ceases operation makes provisions to keep all records, slides, blocks and tissue available for the required periods (42 CFR 493.1105(b)).
- Loan to proficiency testing. Slides may be loaned to a proficiency testing program in place of retention for the required period if the laboratory receives and keeps a written acknowledgment of receipt from the program (42 CFR 493.1274(f)(2)).
- Other loans and referrals. Documentation is kept for slides loaned or referred for purposes other than proficiency testing (42 CFR 493.1274(f)(3)).
- Retrievability. All slides are retrievable upon request (42 CFR 493.1274(f)(4)).
- Proposed retention of digital images. A CMS proposed rule of 8 October 2026 would require laboratories to keep cytology digital images for at least 5 years and histopathology digital images for at least 10 years, alongside the slides. Block retention would stay at 2 years. The rule is proposed and not in effect, and comments close on 7 December 2026 (91 FR 64482–64483, 64527).
Occupational exposure limits for formaldehyde and xylene
| Exposure limit | Value | Source |
|---|---|---|
| Formaldehyde permissible exposure limit, 8-hour time-weighted average | 0.75 ppm | 29 CFR 1910.1048(c)(1) |
| Formaldehyde short-term exposure limit, 15 minutes | 2 ppm | 29 CFR 1910.1048(c)(2) |
| Formaldehyde action level, 8-hour time-weighted average | 0.5 ppm | 29 CFR 1910.1048(b) |
| Xylenes (o-, m-, p-isomers) permissible exposure limit | 100 ppm (435 mg/m³) | 29 CFR 1910.1000, Table Z-1 |
- Formaldehyde training. Training is provided at initial assignment, whenever a new formaldehyde exposure is introduced into the work area, and at least annually thereafter (29 CFR 1910.1048(n)(2)).
Medicare coding of cytopathology specimens
- One code per specimen. For a single specimen, only one code is reported from a group of related codes with the same end result, for example 88104–88112, 88142–88143, 88150–88153 and 88164–88167 (NCCI Chapter X, L.1).
- Fluids, washings and brushings. These are reported with one code from 88104–88112. Codes 88160–88162 ("any other source") are not added for smears from the same fluid (NCCI Chapter X, L.1).
Source: CMS NCCI Policy Manual for Medicare Services, Chapter X, revised 1 January 2026.
Medicare screening Pap tests: frequency and HCPCS codes
- Coverage. Medicare covers a screening Pap smear for a woman who has not had one during the preceding 2 years. Annual screening is covered for a woman of childbearing age whose Pap smear in any of the preceding 3 years showed cervical or vaginal cancer or another abnormality, and for a woman at high risk of cervical cancer whose physician recommends more frequent testing (CMS NCD 210.2).
- High-risk factors. Early onset of sexual activity (under 16 years of age); 5 or more sexual partners in a lifetime; history of sexually transmitted disease, including HIV infection; fewer than 3 negative Pap smears, or none, within the previous 7 years; and DES exposure in utero (CMS NCD 210.2).
- Claims edit. For a low-risk beneficiary, payment may be made after 23 months have passed after the end of the month of the last covered smear. The claim carries a low-risk or high-risk diagnosis code. Z12.4 is a low-risk code for the every-2-years schedule. Z91.89 and the Z72.51–Z72.53 codes are among the high-risk codes for the annual schedule (Medicare Claims Processing Manual, Chapter 18, §30.2 and §30.6).
- HPV co-testing. HPV testing with cytology is covered once every 5 years for asymptomatic beneficiaries aged 30 to 65 years and is billed with G0476 (Medicare Claims Processing Manual, Chapter 18, §30.2.1; NCD 210.2.1).
| HCPCS code | Service | Payment |
|---|---|---|
| Q0091 | Obtaining, preparing and conveying the screening smear to the laboratory | Physician fee schedule |
| P3000 | Screening Papanicolaou smear, up to 3 smears, by a technician under physician supervision | Clinical laboratory fee schedule |
| P3001 | Screening Papanicolaou smear, up to 3 smears, requiring interpretation by a physician | Physician fee schedule |
| G0123 | Liquid-based thin-layer preparation, screening by cytotechnologist under physician supervision | Clinical laboratory fee schedule |
| G0124 | Liquid-based thin-layer preparation, requiring interpretation by physician | Physician fee schedule |
| G0141 | Smears screened by automated system with manual rescreening, requiring interpretation by physician | Physician fee schedule |
| G0143 | Thin-layer preparation with manual screening and rescreening by cytotechnologist | Clinical laboratory fee schedule |
| G0144 | Thin-layer preparation with screening by automated system | Clinical laboratory fee schedule |
| G0145 | Thin-layer preparation with screening by automated system and manual rescreening | Clinical laboratory fee schedule |
| G0147 | Smears screened by automated system under physician supervision | Clinical laboratory fee schedule |
| G0148 | Smears screened by automated system with manual reevaluation | Clinical laboratory fee schedule |
Source: Medicare Claims Processing Manual, Chapter 18, §30.5 (chapter Rev. 13709, issued 2 April 2026). The deductible is waived for all of these codes. Coinsurance applies to the physician fee schedule codes, and neither deductible nor coinsurance applies to the clinical laboratory fee schedule codes.
Errors in cytology laboratory operations
| Situation | Correct application | Source |
|---|---|---|
| A Pap test requisition form omits the last menstrual period | The requisition solicits the last menstrual period and prior abnormal reports, treatment or biopsy | 42 CFR 493.1241(c)(7) |
| A telephone request for added tests is never followed by written authorization | Written or electronic authorization is solicited within 30 days, or efforts to obtain it are documented | 42 CFR 493.1241(b) |
| A rejected specimen is discarded without documentation | The condition and disposition are recorded in the test record | 42 CFR 493.1283(a)(3) |
| Cytology slides are discarded 3 years after examination | Cytology slides are retained for at least 5 years | 42 CFR 493.1105(a)(7)(i)(A) |
| A slide sent to an outside consultant is not logged | Loans and referrals for purposes other than proficiency testing are documented | 42 CFR 493.1274(f)(3) |
| Codes 88104 and 88160 are reported for smears from the same pleural fluid | Only one code from 88104–88112 is reported | NCCI Chapter X, L.1 |
CLIA record and slide retention lookup
Medicolegal Issues and Communication of Cytology Results
Definition. Communication of cytology results covers the content of the cytology report, its release to authorized persons and patients, the notification of urgent and significant unexpected diagnoses, and the correction of errors after sign-out. The federal requirements are in the postanalytic standard for test reports (42 CFR 493.1291) and the reporting provisions of the cytology standard (42 CFR 493.1274(e)). Medicolegal issues in cytology arise mainly from allegedly false-negative cervical cytology. The review of slides in litigation is subject to outcome bias, which blinded review formats are designed to reduce (Austin 1997).
Related page: Gynecologic Cytology Quality Assurance: 10% Rescreening, 5-Year Lookback, Cytologic-Histologic Correlation and Proficiency Testing (lookback review and amended reports after lookback) Related page: CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation (technical supervisor review and signature) Related page: Cytology Laboratory Operations: Requisitions and Specimen Acceptance, Record and Slide Retention, Safety, and Billing and Coding (retention and loan of slides) Related page: Cytology Quality Assurance Metrics, Test Validation and Quality Control (turnaround time and interpretive rates) Related page: The Bethesda System for Reporting Cervical Cytology (terminology of cervical cytology reports)
Content of the cytology report
Report elements required by 42 CFR 493.1291(c) and 493.1274(e)
| Report element | Requirement | Source |
|---|---|---|
| Patient identification | Patient name and identification number, or a unique patient identifier and identification number | 42 CFR 493.1291(c)(1) |
| Testing location | Name and address of the laboratory location where the test was performed | 42 CFR 493.1291(c)(2) |
| Report date | Test report date | 42 CFR 493.1291(c)(3) |
| Test | Test performed | 42 CFR 493.1291(c)(4) |
| Specimen source | When appropriate | 42 CFR 493.1291(c)(5) |
| Result | Result and, if applicable, interpretation | 42 CFR 493.1291(c)(6) |
| Unacceptable specimens | Condition and disposition of specimens that do not meet acceptability criteria | 42 CFR 493.1291(c)(7) |
| Terminology | Narrative descriptive nomenclature for all results | 42 CFR 493.1274(e)(5) |
| Unsatisfactory specimens | Identified and reported as unsatisfactory | 42 CFR 493.1274(e)(4) |
| Supervisory review | Signature or authorized electronic signature reflecting technical supervisor review for abnormal gynecologic and all nongynecologic cases | 42 CFR 493.1274(e)(2) and (3) |
| Corrections | Corrected reports indicate the basis for correction | 42 CFR 493.1274(e)(6) |
- Testing location for remote review. Test reports from remote review of digital materials indicate the site where testing was performed. For a private residence, the laboratory may use a coding system in place of the home address, available on request (CMS QSO-23-15-CLIA, revised 23 September 2025).
- Cytology exception. Since 23 March 2026, remote review of digital cytology images requires a separate CLIA certificate for the remote location (CMS QSO-23-15-CLIA, revised 23 September 2025; 91 FR 64481). A CMS proposed rule of 8 October 2026 would keep this requirement and exclude cytology from the proposed "virtual access" provision. The rule is proposed and not in effect, and comments close on 7 December 2026 (91 FR 64482).
- Educational notes. The Papanicolaou Society of Cytopathology issued guidelines for educational notes, disclaimers and similar comments on cervical cytology reports. They were written to conform to the Bethesda Workshop consensus recommendations and to meet CAP inspection requirements (Papanicolaou Society of Cytopathology 2003).
Release of results and patient access
| Rule | Content | Source |
|---|---|---|
| Accurate transmission | The laboratory has a system to send results accurately, reliably and in a timely manner from data entry to the final report destination, including interfaced systems | 42 CFR 493.1291(a) |
| Authorized recipients | Results are released only to authorized persons, persons responsible for using the results, and the laboratory that requested the test, except as provided for patients | 42 CFR 493.1291(f) |
| Patient access | On request, the laboratory may give patients, their personal representatives and persons specified under 45 CFR 164.524(c)(3)(ii) access to completed test reports identified through the laboratory's authentication process | 42 CFR 493.1291(l) (added at 79 FR 7316, 6 February 2014) |
| Referred specimens | The referring laboratory does not revise the testing laboratory's results, keeps an exact duplicate of each report, and tells the ordering person where testing was performed | 42 CFR 493.1291(i) |
| Ready access to reports | Reports or records of their content are kept so that they can be readily identified and accessed | 42 CFR 493.1291(j) |
| Test information | On request, the laboratory provides a list of test methods, performance specifications and information on interferences | 42 CFR 493.1291(e) |
- Information blocking and portal release. The 21st Century Cures Act sought to eliminate information blocking and requires timely release of electronic health information, including diagnostic results, on request. Some health systems responded by releasing nearly all results to patient portals immediately (Wood et al. 2023).
Communication of urgent and significant unexpected diagnoses
- Regulatory duty. The laboratory immediately alerts the individual or entity requesting the test, and the individual responsible for using the results, when any result indicates an imminently life-threatening condition or a panic or alert value (42 CFR 493.1291(g)).
- Consensus on anatomic pathology. The CAP and the Association of Directors of Anatomic and Surgical Pathology (ADASP) recommended that each institution create its own policy on urgent diagnoses and significant, unexpected diagnoses in surgical pathology and cytology. The policy is separate from critical result or panic value policies in clinical pathology, with a different expected time frame (Nakhleh et al. 2012).
- Clinician and pathologist views. A survey of clinicians and pathologists found important disagreement on which entities should be considered critical and on who is responsible for correlating histologic findings with the wider clinical context. The authors recommended interdepartmental agreement on communication practices, better access to the electronic medical record and clinical history at the pathologist's workstation, and periodic review of the communication process (Cretara and Otis 2018).
| Category | Definition | Communication |
|---|---|---|
| Urgent diagnosis | A medical condition that, in most cases, should be addressed as soon as possible | Under the institutional policy, in a time frame that allows the condition to be addressed as soon as possible |
| Significant, unexpected diagnosis | A medical condition that is clinically unusual or unforeseen and should be addressed at some point in the patient's course | Communication under the institutional policy within its defined time frame |
| Clinical pathology critical value | A result that indicates an imminently life-threatening condition or panic value | Immediate alert under §493.1291(g) and the laboratory's critical value policy |
Sources: Nakhleh et al. 2012 (definitions and separation from clinical pathology policies); 42 CFR 493.1291(g).
Corrected and amended reports
- Regulatory process. When errors in reported results are detected, the laboratory promptly notifies the ordering person and, if applicable, the person using the results, issues corrected reports promptly, and keeps duplicates of both the original and the corrected report (42 CFR 493.1291(k)).
Amended report benchmarks in anatomic pathology
| Measure | Value | Source |
|---|---|---|
| Cases surveyed | 1,667,547 surgical pathology specimens in 359 laboratories | Nakhleh and Zarbo 1998 |
| Mean amended report rate | 1.9 per 1,000 cases (median 1.5 per 1,000) | Nakhleh and Zarbo 1998 |
| Amendments correcting patient identification | 19.2% | Nakhleh and Zarbo 1998 |
| Amendments changing the final diagnosis | 38.7% | Nakhleh and Zarbo 1998 |
| Amendments changing a preliminary written diagnosis | 15.6% | Nakhleh and Zarbo 1998 |
| Amendments changing other clinically significant information | 26.5% | Nakhleh and Zarbo 1998 |
| Most common trigger for detection | Clinician request to review a case (20.5%) | Nakhleh and Zarbo 1998 |
| Effect of slide review before sign-out | Lower rates of amended reports that changed the final diagnosis or other significant information | Nakhleh and Zarbo 1998 |
Case review to reduce interpretive error
- 2016 guideline. The CAP and ADASP guideline on interpretive diagnostic error reduction in surgical pathology and cytology made 5 recommendations: anatomic pathologists develop procedures for review of cases to detect disagreements and potential interpretive errors, perform reviews in a timely manner, document review procedures relevant to their practice setting, monitor and document the results of reviews, and take steps to improve agreement when reviews show poor agreement within a defined case type (Nakhleh et al. 2016).
- 2026 update. A 2026 update of the guideline, prompted by new evidence and the adoption of digital technologies including artificial intelligence, established 2 strong recommendations and 4 good practice statements. The panel recommended that anatomic pathologists implement procedures for case review to detect and correct potential interpretive errors (Dintzis et al. 2026).
- Error frequency. A CAP Q-Probes study based on secondary review found a mean laboratory anatomic pathology error frequency of 6.7%.
Medicolegal issues in cytology
Claims and recurring patterns in allegedly missed cervical cytology
Recurring patterns in litigated cervical cytology are small-cell variants of HSIL present in small numbers, hyperchromatic crowded cell groups, atypical squamous cells of undetermined significance, smears taken during menses and other bloody smears (particularly with degeneration or heavy inflammation), atypical repair and unsatisfactory samples (Frable 2007).
- Claim frequency and severity. In one insurer's data for 2000 to 2003, claims for missed cervical cytology ranked third among claims against pathologists, after breast biopsies and pigmented skin lesions. Their severity, almost $700,000 per claim, was second only to that of claims concerning melanoma (Frable 2007).
- Inherent false-negative rate. The sensitivity of the Pap test is below 100% (Renshaw 2002), so some negative reports precede a later diagnosis of a lesion.
Outcome bias and blinded review of litigated Pap tests
- Biased retrospective review. Review of litigated Pap slides usually takes place with knowledge of the adverse outcome and of the litigation, and with more time per slide than routine screening allows. Factors that restrain overinterpretation in daily practice, such as concern about false-positive diagnoses and unnecessary procedures, are absent, which favors overly aggressive interpretation (Austin 1997).
- Blinded review formats. Blinded review formats simulate normal prospective screening. Austin considered the difficulty of the slide, measured by blinded rescreening, the second most important factor after overall laboratory performance in deciding whether a reasonable standard of practice was followed (Austin 1997).
Risk management of allegedly false-negative cervical cytology
- Written procedure. Procedures for administering and reporting retrospective reviews under CLIA should be outlined in a peer-reviewed procedure document, reviewed and approved by risk managers or insurers, and documented to obtain maximal protection from legal discovery (Frable 2007).
- Clinical context. Clinical vigilance, attention to unexplained symptoms and signs, and biopsy of any visible cervical abnormality are part of reducing risk from allegedly false-negative samples (Frable 2007).
Errors in communication and medicolegal practice
| Situation | Correct application | Source |
|---|---|---|
| A corrected report replaces the original in the record without a trace | Duplicates of the original and corrected reports are maintained | 42 CFR 493.1291(k)(3) |
| A corrected report states the new diagnosis only | The corrected report indicates the basis for correction | 42 CFR 493.1274(e)(6) |
| An unexpected malignancy on a cytology specimen is handled under the chemistry panic-value policy | Anatomic pathology urgent and significant unexpected diagnoses follow a separate institutional policy | Nakhleh et al. 2012 |
| A litigated slide is reviewed by an expert who knows the outcome | Blinded review formats limit outcome bias | Austin 1997 |
| A slide is released to an attorney without a log entry | Loans for purposes other than proficiency testing are documented and slides stay retrievable | 42 CFR 493.1274(f)(3) and (f)(4) |
| A reference laboratory's report is edited by the referring laboratory | The referring laboratory does not revise the testing laboratory's results | 42 CFR 493.1291(i)(1) |
References
- Arbyn M, Schenck U, Ellison E, Hanselaar A. Metaanalysis of the accuracy of rapid prescreening relative to full screening of pap smears. Cancer. 2003;99(1):9–16. doi:10.1002/cncr.10921. PMID 12589640
- Austin RM. Results of blinded rescreening of Papanicolaou smears versus biased retrospective review. Arch Pathol Lab Med. 1997;121(3):311–314. PMID 9111125
- Biscotti CV, Dawson AE, Dziura B, et al. Assisted primary screening using the automated ThinPrep Imaging System. Am J Clin Pathol. 2005;123(2):281–287. PMID 15842055
- Booth CN, Bashleben C, Filomena CA, et al. Monitoring and ordering practices for human papillomavirus in cervical cytology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 5. Arch Pathol Lab Med. 2013;137(2):214–219. doi:10.5858/arpa.2012-0114-CP. PMID 23368863
- Brainard JA, Birdsong GG, Elsheikh TM, et al. Prospective and retrospective review of gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 2. Arch Pathol Lab Med. 2013;137(2):175–182. doi:10.5858/arpa.2012-0178-OA. PMID 23368859
- Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments of 1988 (CLIA); virtual access, gynecologic cytology proficiency testing (PT), personnel qualifications, and other changes. Proposed rule. Fed Regist. 2026;91:64480–64530. FR Doc 2026-20613.
- Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Chapter 18: Preventive and screening services, §30 (Rev. 13709, issued 2 April 2026). https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c18.pdf
- Centers for Medicare & Medicaid Services. National Correct Coding Initiative Policy Manual for Medicare Services, Chapter X: Pathology/laboratory services, CPT codes 80000–89999. Revised 1 January 2026. https://www.cms.gov/files/document/10-chapter10-ncci-medicare-policy-manual-2026-final.pdf
- Centers for Medicare & Medicaid Services. National Coverage Determination 210.2: Screening Pap smears and pelvic examinations for early detection of cervical or vaginal cancer. Version 3, effective 19 June 2006. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=185
- Centers for Medicare & Medicaid Services. Proficiency testing program requirements: general and cytology. https://www.cms.gov/medicare/health-safety-standards/clinical-laboratory-improvement-amendments-clia/clia-regulations-compliance/proficiency-testing-program-requirements-general-cytology
- Centers for Medicare & Medicaid Services. QSO-23-15-CLIA, revised: CLIA post-public health emergency guidance. 23 September 2025. https://www.cms.gov/files/document/qso-23-15-clia-revised-2025-09-23.pdf
- Centers for Medicare & Medicaid Services. Specialty/subspecialty information for approved accreditation organizations under CLIA. September 2026. https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/aolist.pdf
- Clary KM, Davey DD, Naryshkin S, et al. The role of monitoring interpretive rates, concordance between cytotechnologist and pathologist interpretations before sign-out, and turnaround time in gynecologic cytology quality assurance: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 1. Arch Pathol Lab Med. 2013;137(2):164–174. doi:10.5858/arpa.2012-0120-CC. PMID 23368858
- College of American Pathologists. Laboratory Accreditation Program. https://www.cap.org/laboratory-improvement/accreditation/laboratory-accreditation-program
- College of American Pathologists. Principles of analytic validation of immunohistochemical assays (guideline page and summary of the 2024 update). https://cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/principles-of-analytic-validation-of-immunohistochemical-assays
- Cretara AD, Otis CN. Perspectives and perceptions of urgent and alert values in surgical pathology and cytopathology: a survey of clinical practitioners and pathologists. Cancer Cytopathol. 2018;126(12):970–979. doi:10.1002/cncy.22067. PMID 30291817
- Crothers BA, Booth CN, Darragh TM, et al. False-positive Papanicolaou (PAP) test rates in the College of American Pathologists PAP education and PAP proficiency test programs: evaluation of false-positive responses of high-grade squamous intraepithelial lesion or cancer to a negative reference diagnosis. Arch Pathol Lab Med. 2014;138(5):613–619. doi:10.5858/arpa.2013-0083-CP. PMID 24786119
- Crothers BA, Darragh TM, Tambouret RH, et al. Trends in cervical cytology screening and reporting practices: results from the College of American Pathologists 2011 PAP Education Supplemental Questionnaire. Arch Pathol Lab Med. 2016;140(1):13–21. doi:10.5858/arpa.2015-0004-CP. PMID 26046490
- Crothers BA, Jones BA, Cahill LA, et al. Quality improvement opportunities in gynecologic cytologic-histologic correlations: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 4. Arch Pathol Lab Med. 2013;137(2):199–213. doi:10.5858/arpa.2012-0250-OA. PMID 23368862
- Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128(11):1224–1229. doi:10.5858/2004-128-1224-BIARRP. PMID 15504056
- Dintzis SM, Evans JJ, Hernandez M, et al. Interpretive diagnostic error reduction: guideline update from the College of American Pathologists in collaboration with the Association of Directors of Anatomic and Subspecialty Pathology. Arch Pathol Lab Med. 2026;150(9):668–677. doi:10.5858/arpa.2026-0016-CP. PMID 42203216
- Ducatman BS, Bentz JS, Fatheree LA, et al. Gynecologic cytology proficiency testing failures: what have we learned? Observations from the College of American Pathologists gynecologic cytology proficiency testing program. Arch Pathol Lab Med. 2011;135(11):1442–1446. doi:10.5858/arpa.2010-0681-SA. PMID 22032572
- Electronic Code of Federal Regulations. 29 CFR 1910.1000, Air contaminants, Table Z-1. https://www.ecfr.gov/current/title-29/subtitle-B/chapter-XVII/part-1910/subpart-Z/section-1910.1000
- Electronic Code of Federal Regulations. 29 CFR 1910.1048, Formaldehyde (current to 2 November 2026). https://www.ecfr.gov/current/title-29/subtitle-B/chapter-XVII/part-1910/subpart-Z/section-1910.1048
- Electronic Code of Federal Regulations. 42 CFR Part 493, Laboratory requirements (current to 2 November 2026), including §§493.1, 493.2, 493.5, 493.551, 493.1201, 493.1235, 493.1274, 493.1449, 493.1451, 493.1467–493.1485, 493.1777 and 493.1780. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493
- Elsheikh TM, Austin RM, Chhieng DF, Miller FS, Moriarty AT, Renshaw AA; American Society of Cytopathology. American Society of Cytopathology workload recommendations for automated Pap test screening: developed by the productivity and quality assurance in the era of automated screening task force. Diagn Cytopathol. 2013;41(2):174–178. doi:10.1002/dc.22817. PMID 22351120
- Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331–335. doi:10.5858/134.3.331. PMID 20196659
- Frable WJ. Error reduction and risk management in cytopathology. Semin Diagn Pathol. 2007;24(2):77–88. doi:10.1053/j.semdp.2007.03.006. PMID 17633349
- Frable WJ. Guidelines for experts reviewing Papanicolaou smear litigation cases. Arch Pathol Lab Med. 1997;121(3):331–334. PMID 9111129
- Goldsmith JD, Troxell ML, Roy-Chowdhuri S, et al. Principles of analytic validation of immunohistochemical assays: guideline update. Arch Pathol Lab Med. 2024;148(6):e111–e153. doi:10.5858/arpa.2023-0483-CP. PMID 38391878
- Harinath L, Elishaev E, Matsko J, et al. Determination of an optimal quality control method for Pap test analysis using digital cytology and artificial intelligence. J Am Soc Cytopathol. 2026;15(5):369–377. doi:10.1016/j.jasc.2026.04.005. PMID 42168041
- Howell LP, Nayar R, Savaloja L, et al. The role of proficiency testing in ensuring quality: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 3. Arch Pathol Lab Med. 2013;137(2):183–189. doi:10.5858/arpa.2012-0094-OA. PMID 23368860
- Jones BA, Novis DA. Cervical biopsy-cytology correlation: a College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories. Arch Pathol Lab Med. 1996;120(6):523–531. PMID 8651852
- Jones BA, Novis DA. Nongynecologic cytology turnaround time: a College of American Pathologists Q-Probes study of 180 laboratories. Arch Pathol Lab Med. 2001;125(10):1279–1284. doi:10.5858/2001-125-1279-NCTT. PMID 11570901
- Lin O, Alperstein S, Barkan GA, et al. American Society of Cytopathology telecytology validation recommendations for rapid on-site evaluation (ROSE). J Am Soc Cytopathol. 2024;13(2):111–121. doi:10.1016/j.jasc.2023.12.001. PMID 38310002
- Nakhleh RE, Myers JL, Allen TC, et al. Consensus statement on effective communication of urgent diagnoses and significant, unexpected diagnoses in surgical pathology and cytopathology from the College of American Pathologists and Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med. 2012;136(2):148–154. doi:10.5858/arpa.2011-0400-SA. PMID 21992705
- Nakhleh RE, Nosé V, Colasacco C, et al. Interpretive diagnostic error reduction in surgical pathology and cytology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med. 2016;140(1):29–40. doi:10.5858/arpa.2014-0511-SA. PMID 25965939
- Nakhleh RE, Zarbo RJ. Amended reports in surgical pathology and implications for diagnostic error detection and avoidance: a College of American Pathologists Q-Probes study of 1,667,547 accessioned cases in 359 laboratories. Arch Pathol Lab Med. 1998;122(4):303–309. PMID 9648896
- Nomani L, Abro S, Chatt G, et al. Five-year retrospective review in gynecologic cytopathology: is it time to amend? J Am Soc Cytopathol. 2021;10(2):141–147. doi:10.1016/j.jasc.2020.11.001. PMID 33422455
- Papanicolaou Society of Cytopathology Practice Guidelines Task Force. Papanicolaou Society of Cytopathology guidelines for educational notes, disclaimers, and similar comments on reports of cervical cytology specimens. Diagn Cytopathol. 2003;28(5):282–285. doi:10.1002/dc.10284. PMID 12722126
- Raab SS. Improving patient safety through quality assurance. Arch Pathol Lab Med. 2006;130(5):633–637. doi:10.5858/2006-130-633-IPSTQA. PMID 16683878
- Renshaw AA, Elsheikh TM. Assessment of manual workload limits in gynecologic cytology: reconciling data from 3 major prospective trials of automated screening devices. Am J Clin Pathol. 2013;139(4):428–433. doi:10.1309/AJCP23YDFKKQNUAO. PMID 23525612
- Renshaw AA. Measuring sensitivity in gynecologic cytology: a review. Cancer. 2002;96(4):210–217. doi:10.1002/cncr.10717. PMID 12209662
- Renshaw AA. Rescreening in cervical cytology for quality control: when bad data is worse than no data or what works, what doesn't, and why. Clin Lab Med. 2003;23(3):695–708. doi:10.1016/s0272-2712(03)00054-4. PMID 14560535
- Tworek J, Nayar R, Savaloja L, et al. General quality practices in gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 3. Arch Pathol Lab Med. 2013;137(2):190–198. doi:10.5858/arpa.2012-0117-CC. PMID 23368861
- Tworek JA, Henry MR, Blond B, et al. College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference on good laboratory practices in gynecologic cytology: background, rationale, and organization. Arch Pathol Lab Med. 2013;137(2):158–163. doi:10.5858/arpa.2012-0111-CC. PMID 23368857
- Underwood DL, Chaari RR, Webb S, Booth CN, Doxtader EE. Evaluation of the Hologic Genius Digital Diagnostics System for clinical use in Papanicolaou test interpretation: a validation study of 1748 cases. J Am Soc Cytopathol. 2026;15(5):378–384. doi:10.1016/j.jasc.2026.05.004. PMID 42309847
- US Food and Drug Administration. De Novo request DEN210035: Genius Digital Diagnostics System with the Genius Cervical AI algorithm (Hologic, Inc.), granted 31 January 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN210035
- US Food and Drug Administration. How laboratorians can safely calculate workload for FDA-approved semi-automated gynecologic cytology screening devices. 2010. Archived as CLIAC February 2012 meeting reference (Tab 28): https://www.cdc.gov/cliac/docs/addenda/cliac0212/Tab_28_CLIAC_2012Feb_Reference04_Cytology_FDASafetyTip.pdf
- Wilbur DC, Black-Schaffer WS, Luff RD, et al. The Becton Dickinson FocalPoint GS Imaging System: clinical trials demonstrate significantly improved sensitivity for the detection of important cervical lesions. Am J Clin Pathol. 2009;132(5):767–775. doi:10.1309/AJCP8VE7AWBZCVQT. PMID 19846820
- Wood KE, Pham HT, Carter KD, Nepple KG, Blum JM, Krasowski MD. Impact of a switch to immediate release on the patient viewing of diagnostic test results in an online portal at an academic medical center. J Pathol Inform. 2023;14:100323. doi:10.1016/j.jpi.2023.100323. PMID 37520309